PLYMOUTH
MEETING, Pa., Sept. 26,
2024 /PRNewswire/ -- Harmony Biosciences Holdings,
Inc. (Nasdaq: HRMY), will provide an overview of its robust,
late-stage pipeline at an in-person Investor Day at 8:30 a.m. ET on October
1 in New York City. Members
of Harmony's senior leadership team along with therapeutic area key
opinion leaders will present to investors and research analysts the
following:
- Highlights of the company's late-stage pipeline with key
program updates, including:
New data on pitolisant in idiopathic hypersomnia
(IH)
Update on pitolisant-HD development program
New data on BP1.15205, a potential best in class
orexin-2 agonist
- Scientific rationale for therapeutic efficacy based on
mechanisms of action for ZYN002 and EPX100, both
in registrational Phase 3 trials
- Market potential for late-stage pipeline assets following
recent acquisitions; portfolio now includes three
orphan/rare CNS franchises, each with potential peak sales
opportunities of $1B - $2B
The Harmony Investor Day presentation will be made available
following the conclusion of the event on the Investors page of the
Harmony Biosciences website. Investors interested in attending the
event should contact Brennan Doyle
at Harmony Investor Relations at bdoyle@harmonybiosciences.com or
register here to attend in person or participate virtually.
Space is limited.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to
developing and commercializing innovative therapies for patients
with rare neurological diseases who have unmet medical needs.
Driven by novel science, visionary thinking, and a commitment to
those who feel overlooked, Harmony Biosciences is nurturing a
future full of therapeutic possibilities that may enable patients
with rare neurological diseases to truly thrive. Established by
Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, we believe that when
empathy and innovation meet, a better future can begin; a vision
evident in the therapeutic innovations we advance, the culture we
cultivate, and the community programs we foster. For more
information, please visit www.harmonybiosciences.com.
Forward Looking Statement:
This presentation includes forward‐looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts
contained in these materials or elsewhere, including statements
regarding Harmony Biosciences Holdings, Inc.'s (the "Company")
future financial position, business strategy and plans and
objectives of management for future operations, should be
considered forward-looking statements. Forward-looking statements
use words like "believes," "plans," "expects," "intends," "will,"
"would," "anticipates," "estimates," "may," "could," "might,"
"continue," "potential," and similar words or expressions in
discussions of the Company's future operations, financial
performance or the Company's strategies, but the absence of these
words does not mean that a statement is not forward-looking. These
statements are based on current expectations or objectives that are
inherently uncertain. These forward-looking statements involve
significant risks and uncertainties that could cause the actual
results to differ materially from the expressed or implied
forwarding-looking statements, including, but not limited to the
risk factors discussed under the caption "Risk Factors" in the
Company's Annual Report on Form 10-K filed with the U.S. Securities
and Exchange Commission (the "SEC") on February 22, 2024 and its other filings with the
SEC. While the Company may elect to update such forward-looking
statements at some point in the future, it disclaims any obligation
to do so, even if subsequent events cause its views to
change.
This presentation includes information related to market
opportunity as well as cost and other estimates obtained from
internal analyses and external sources. The internal analyses are
based upon management's understanding of market and industry
conditions and have not been verified by independent sources.
Similarly, the externally sourced information has been obtained
from sources the Company believes to be reliable, but the accuracy
and completeness of such information cannot be assured. Neither the
Company, nor any of its respective officers, directors, managers,
employees, agents, or representatives, (i) make any representations
or warranties, express or implied, with respect to any of the
information contained herein, including the accuracy or
completeness of this presentation or any other written or oral
information made available to any interested party or its advisor
(and any liability therefore is expressly disclaimed), (ii) have
any liability from the use of the information, including with
respect to any forward-looking statements, or (iii) undertake to
update any of the information contained herein or provide
additional information as a result of new information or future
events or developments.
Harmony Biosciences Investor Contact:
Brennan
Doyle
484-539-9700
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-host-first-investor-day-on-october-1-2024-302259359.html
SOURCE Harmony Biosciences